should proceed thoughtfully, guided by a coalition of stakeholders dedicated to delivering highquality, patient-centered care while collecting the data necessary to determine optimal patient selection, effectiveness, and safety. This document seeks to highlight the critical issues surrounding LAA occlusion therapies and to facilitate the alignment of multiple interests, including those of patients and their families, primary care physicians, general and geriatric cardiologists, other heart team members, procedural specialists * (i.e., electrophysiologists and interventional cardiologists), regulators, payers, professional societies, and industry.
The American College of Cardiology (ACC), the Heart Rhythm Society (HRS), and the restrictions are not applied to participation in the external peer review process for clinical documents; however, for the purposes of full disclosure, all relevant RWI for reviewers, as well as their individual affiliations, are published in Appendix 2. Final review and approval of the document were provided by the respective boards of the 3 professional societies. The writing group also includes a non-medical representative with AF in order to provide a patient perspective during document development.
Introduction
Percutaneous LAA occlusion has the potential to change the clinical approach to stroke prevention in selected patients with AF. On the basis of data from large, prospective randomized controlled trials, oral anticoagulants such as warfarin, factor Xa inhibitors, and direct thrombin inhibitors have become the current standard of care to reduce the risk of stroke in patients with risk factors, albeit at the expense of an increase in bleeding risk (1) (2) (3) . Some patients with AF whose stroke risk profiles would favor anticoagulation have relative or absolute contraindications to anticoagulation. Others are unable or unwilling to adhere to long-term anticoagulation therapy.
Thus, alternatives to pharmacological therapy to reduce the risk of stroke have been pursued.
In contrast to many technologies, percutaneous approaches to LAA occlusion have been developed simultaneously through multiple pathways, including the off-label use of FDAapproved devices (e.g., LARIAT, atrial and ventricular septal defect occlusion devices), use of devices intended for LAA occlusion available in other countries through local regulatory pathways, and the FDA Pivotal Trial Pathway for class III medical devices. In order to promote the diffusion of this technology in a manner that will optimize patient outcomes, it will be necessary to develop and implement new guidelines, expert consensus statements, requirements for training, operator credentialing, and institutional polices.
Key Questions
Several questions are relevant to the diffusion of percutaneous LAA occlusion device technologies into clinical practice:
1. Will the technology be available in all centers or will it be restricted to specialized centers? If the latter, how will these centers be specified? What constitutes an LAA occlusion device center of excellence?
2. What training will be required for procedural specialists, and how will it be provided? What criteria will be utilized for the granting and maintenance of procedural privileges? Answers to these questions are complex and partly influenced by the number of interested stakeholders. Percutaneous LAA occlusion is technically challenging and may be achieved through different approaches (e.g. internal occlusion, external ligation) that may vary in efficacy and safety. As these technologies become available as potential alternatives to anticoagulation for stroke prevention in AF, it will be important for experienced centers and cohesive teams to guide deployment into clinical practice. Furthermore, mechanisms to rigorously evaluate the short-and long-term safety, comparative effectiveness, and cost effectiveness of these approaches that are supported by relevant stakeholders must be developed.
Stroke Prevention In Atrial Fibrillation: Current Evidence and Guidelines
Atrial fibrillation affects as many as 6.1 million individuals in the United States and may account for as many as 1 in 5 strokes in persons aged over 80 years (4) . Evidence supports the hypothesis that, for patients with nonvalvular AF, the LAA is the most common source of thrombus resulting in stroke (5-7). Based on numerous randomized clinical trials, chronic anticoagulationtraditionally with warfarin and more recently with direct thrombin and factor Xa inhibitors-has been established as the standard of care for stroke prevention in patients with AF who have an elevated stroke risk profile provided that the risk of bleeding is not prohibitive (3) . 
Background
Mechanical approaches to LAA occlusion have been used for more than a half-century in cardiac surgery. Initial surgical techniques, typically performed concomitantly with mitral valve surgery or surgical maze procedures, were challenged by the fragility of the LAA, with mechanical complications resulting in hemorrhage during surgical suturing or stapling (5, (10) (11) (12) (13) . Also, surgical closure of the LAA was often incomplete, raising concerns about the discontinuation of pharmacological anticoagulation (12, 14) . These issues contributed to the premature abandonment of the only randomized surgical trial undertaken to objectively evaluate the effectiveness and safety of surgical LAA ligation (15) . A larger study with a target enrollment of 4,700 patients is in progress (16) . More recently, percutaneous LAA occlusion has been proposed as an alternative approach to stroke prevention in patients with nonvalvular AF.
On the basis of the lessons from surgical closure and a continued belief that elimination of the LAA as a source of systemic thromboembolism could be an effective alternative to pharmacological anticoagulation for patients with AF, a Nitinol plug with a fabric component, termed the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) device, was designed for percutaneous insertion via femoral venous access and atrial septal puncture (17) .
Small case series, primarily from Europe but also from North America, were reported before the WATCHMAN supplanted this device. The WATCHMAN, also a Nitinol plug with fabric (in this case fenestrated), was, in turn, assessed in a small pilot study (18) . Despite considerable barriers to conducting randomized trials comparing a device with standard pharmacotherapy, and marked evolution in the agents available for thromboembolic prophylaxis for AF, 2 randomized studies were performed. Simultaneously, other technologies have been developed that, along with the WATCHMAN, have been available outside the United States for several years.
This brief literature review will focus on the published evidence, including the PROTECT AF and PREVAIL trials of the WATCHMAN, and briefly describes other LAA percutaneous occlusion and suture devices for which data are being accumulated.
WATCHMAN
Two randomized controlled trials and several observational studies comprise data from more than 2,400 patients with nonvalvular AF in whom the WATCHMAN device has been implanted for stroke risk reduction (6, 9, 19, 20) . The first and largest randomized controlled trial to evaluate the non-inferiority of a LAA occlusion therapy for stroke risk reduction (PROTECT AF) enrolled M A N U S C R I P T PROTECT AF was designed to assess the non-inferiority of WATCHMAN compared with warfarin for the composite endpoint of ischemic or hemorrhagic stroke, cardiovascular or unexplained death, or systemic embolus. The primary safety endpoint included events related to bleeding (e.g. intracranial, gastrointestinal) or procedural-related complications (e.g., serious pericardial effusion, device embolization, procedure-related stroke). Event rates were calculated as the number of events per 100 patient-years of follow-up. The study was designed to utilize a Bayesian sequential model to limit the study size, with analysis planned once follow-up of 600 patient-years was reached and then every 150 patient-years until follow-up of 1500 patient-years was achieved. Investigators selected a 1-sided probability criterion of non-inferiority for the intervention of at least 97.5%, using a 2-fold non-inferiority margin. ratio for a primary effectiveness endpoint of 2.0 (meaning that the WATCHMAN arm could be found non-inferior to warfarin with an event rate up to twice that observed in the control arm) (19, 21) . It was also recognized that acute procedure-related safety events, which comprised 56%
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(27/48) of safety events in the trial, should be considered separately from long-term events in order to understand the effectiveness of the device in preventing thromboembolic strokes versus procedural learning curves (9, 22) . The PREVAIL trial (20) was designed by the sponsor in conjunction with the FDA in response to the FDA's concerns regarding the PROTECT AF trial (24) . Patients studied in PREVAIL were required to have a CHADS 2 score ≥2.0 (or CHADS 2 =1 with additional stroke risk factors) in order to evaluate the effectiveness of WATCHMAN in a population at relatively high risk for thromboembolic events (3, 21) . Patients requiring chronic antiplatelet therapy with clopidogrel were excluded. To further evaluate the relationship between procedural volume and safety, the PREVAIL protocol required that at least 20% of enrolling sites and operators have no prior experience placing the WATCHMAN device. Study endpoints were the following.
• First primary endpoint ("primary efficacy"): the occurrence of stroke (ischemic or hemorrhagic), cardiovascular or unexplained death, and systemic embolism over 18 months.
• Second primary endpoint ("late ischemic efficacy"): the occurrence of ischemic stroke and systemic embolism from 8 days after randomization and onward, excluding periprocedural events in order to evaluate the mechanism of action of stroke prevention over 18 months.
• Third primary endpoint (mechanistic endpoint): the occurrence of all-cause death, ischemic stroke, systemic embolism, or device-or procedure-related events requiring open cardiac surgery or major endovascular intervention such as pseudo-aneurysm repair, arteriovenous fistula repair, or other major endovascular repair occurring between the time of randomization and within 7 days of the procedure or by hospital discharge, whichever was later.
A non-inferiority hypothesis for the first and second primary endpoints was specified in terms of the 18-month risk ratio (1.75 for the first primary endpoint; 2.0 for the second primary endpoint). Non-inferiority for WATCHMAN device versus warfarin would be achieved if the non-inferiority criteria for both the first and second primary endpoints were met. The safety of the M A N U S C R I P T
device implant procedure was to be deemed acceptable if the third primary endpoint was reached in less than 2.67% of subjects receiving WATCHMAN, an estimated complication rate derived from literature review and agreed upon by sponsor and FDA.
PREVAIL was designed with a non-inferiority Bayesian statistical analysis and incorporated data from PROTECT AF, which was discounted 50% for the first and second primary endpoint analysis, and was not discounted for the third primary endpoint analysis (20) . Because PREVAIL used a more restrictive CHADS 2 inclusion criterion (i.e. higher estimated stroke risk profile) than did PROTECT AF, the prior data borrowed from PROTECT AF included only subjects who would have met the CHADS 2 inclusion criterion used for PREVAIL. PREVAIL enrolled 461 subjects, including 269 randomized to WATCHMAN, 138 to Control (2:1 randomization), and 54
"roll-in" subjects. The study was performed at 50 U.S. sites. The protocol specified that at least 20% of randomized patients would be enrolled in institutions that had not participated in previous WATCHMAN studies, and at least 25% of the randomized patients were to be treated by new operators.
The second FDA panel to review the WATCHMAN device was convened in December 2013 (20) . The data presented at this time included only the early results of PREVAIL. The rates of the first co-primary outcome at 18 months (the composite of stroke, systemic embolism, and cardiovascular/unexplained death) were 6.4% in those treated with the WATCHMAN device versus 6.3% in the warfarin-treated arm, not meeting the criteria for non-inferiority. The second co-primary outcome (stroke or systemic embolism after 7 days of randomization) occurred in 2.5% versus 2.0% in the WATCHMAN and warfarin-treated arms, respectively, which met criteria for non-inferiority. Because the design specified that both of these endpoints meet noninferiority, the trial did not meet overall criteria for non-inferiority. There were no procedurerelated deaths; the primary safety endpoint (a composite of all-cause death, ischemic stroke, systemic embolism, or device-/procedure-related events requiring open cardiovascular surgery or major endovascular intervention) occurred in 2.2% of patients in the WATCHMAN arm, a lower rate than in the PROTECT trial, meeting the pre-specified non-inferiority criteria, albeit with only 18-month follow-up completed. The risk of pericardial effusion requiring drainage was 1.5% in the WATCHMAN arm, also lower than in PROTECT.
Additional data from PREVAIL that became available after the second FDA panel review led to an unprecedented third Circulatory Systems Advisory Panel review on October 8, 2014 (25) .
Eight additional ischemic strokes occurred in the additional follow-up period, all of which occurred in the WATCHMAN group; thus there were 13 ischemic strokes in the WATCHMAN arm versus 1 in the control arm (rate ratio 0.15, p=0.044). Hemorrhagic strokes were rare in both M A N U S C R I P T The risk of ischemic strokes was statistically significantly higher in the WATCHMAN group. Of the 14 WATCHMAN subjects who suffered an ischemic stroke or systemic embolism, only 1 had an event related to the implant procedure. The remaining 12 ischemic strokes and 1 systemic embolism event occurred at a mean of 15 ±8 months post-implant (range 2 to 26 months). Of note, the ischemic stroke rate in the warfarin control group was unexpectedly low (1 subject with 140.1 total patient-years of follow up).
Notably, data on the use of the WATCHMAN in patients for whom anticoagulation therapy is considered contraindicated are limited. In a single case series, 150 patients with nonvalvular AF and CHADS 2 scores ≥1 who were deemed unsuitable for anticoagulation were followed for a mean duration of 14.4 months. Procedure-or device-related safety events occurred in 13 patients (8.7%). Stroke or systemic embolism occurred in 4 (2.3%), which was lower than the 7.3% that was expected given the CHADS 2 scores (26).
On March 13, 2015, the FDA issued an approval for the WATCHMAN device. The approval specified indications for use in patients with nonvalvular AF who are 1) at increased risk of stroke and systemic embolism based upon CHADS 2 or CHA 2 DS 2 -VASc scores; 2) deemed by their physicians to be suitable for warfarin therapy; and 3) have an appropriate rationale to seek a nonpharmacological alternative to warfarin, taking into account the safety and efficacy of the device compared with warfarin (27).
Amplatzer Cardiac Plug
At least 4 Amplatzer devices (St. Jude Medical) have been utilized for LAA occlusion: the atrial septal occluder (ASO), the ventricular septal defect occluder, the Cardiac Plug (ACP), and the Amulet™. The ASO, designed for closure of atrial septal defects, was initially used off label when the first reports of percutaneous LAA device closure were published (28); however, there was a high risk of device embolization, which was attributed to the lack of active fixation anchoring struts (28, 29) . The ASO design was modified for LAA occlusion, maintaining the selfexpandable Nitinol platform with a distal lobe and proximal disk to occlude the LAA ostium with expansion (30) . Clinical feasibility trials have been performed and an investigational device exemption was issued by the FDA, which led to a U.S. pilot study. A pivotal trial in the United
States, similar to PROTECT AF and PREVAIL, was designed to randomize patients to ACP or M A N U S C R I P T 
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LARIAT
The LARIAT device is deployed by means of a trans-pericardial approach using an epicardial snare with a pre-tied suture to lasso and occlude the LAA ( 
Other Percutaneous Devices and Surgical Approaches
Other 
Deployment of the clip via a minimally invasive thoracoscopic approach has been reported (48).
A phase 2 multicenter non-randomized study is now underway to evaluate the safety of this technique for patients deemed at too high a risk to receive long-term oral anticoagulation (49) .
The efficacy of the device to reduce the risk of thromboembolic stroke has not been evaluated.
Care Team and Facilities
Multidisciplinary Heart Team
The multidisciplinary heart team model has been widely embraced in the area of percutaneous valve replacement therapy (50) and serves as a template for care around other complex percutaneous cardiovascular procedures. The multidisciplinary heart team extends well beyond collaboration between individual clinicians; depending on the type of procedure, it may include collaboration among a wide variety of physician and non-physician specialties. A multidisciplinary approach is applicable to LAA occlusion, although the specific composition of the team will likely differ from that employed for valve procedures. The initial evaluation should be performed by both an individual with the expertise to characterize the specific risks and benefits of medical therapy and a procedural specialist, who can estimate the risks and benefits of a proposed procedure. The procedural specialist should also have expertise related to medical therapy for stroke prevention in AF. Beyond the initial evaluation, any input and/or participation in evaluating and managing this procedure should include expertise in echocardiography, X-ray imaging modalities (primarily CT), and in anesthesiology when general anesthesia is planned. A cardiac surgeon should be available for surgical backup in case of emergency. The multidisciplinary heart team must work together, particularly with respect to patient evaluation and selection, pre-procedural evaluation, intra-procedural management, post-procedural management, post-discharge follow-up, and outcome analysis.
General Requirements
One of the cornerstones of a structural heart disease and/or electrophysiology (EP) program is a well-formulated, collaborative effort among all members of the care team. Depending on the type of procedure and device used, close collaboration may be required between procedural specialists, physician echocardiographers, sonographers, radiologists, hematologists, neurologists, and cardiac surgeons to ensure proper patient selection, evaluation, and execution of LAA occlusion.
In some cases, expertise in other areas may be required to inform decision making (e.g. geriatric M A N U S C R I P T
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medicine and/or gastroenterology or urology for patients with a history of significant gastrointestinal or genitourinary bleeding, respectively).
Irrespective of their specialty, physicians performing these procedures should possess the appropriate cognitive and technical skillsets. They should have an understanding of stroke and stroke syndromes, AF, the pharmacology of anticoagulants, and the regional anatomy of the left atrium and LAA. They should also possess the requisite technical procedural skills. LAA occlusion procedures are complex and should be performed in institutions with experience in advanced structural heart disease procedures and/or EP procedures that require access to the left atrium. The ability to interpret echocardiographic, CT, and/or MRI data pre-, intra-, and postprocedurally is essential. Procedural echocardiographic guidance is also necessary; the physician echocardiographer must be familiar with the procedure and committed to being available throughout the case. Both randomized and non-randomized studies of LAA occlusion suggest a relationship between operator procedural experience and both successful device delivery and the avoidance of complications such as cardiac perforation and cardiac tamponade. Collectively, members of the multidisciplinary heart team must be skilled in imaging of the LAA, trans-septal techniques, percutaneous pericardial puncture, advanced retrieval techniques, and large vessel
access. An understanding of the interplay between wires, catheters, and left atrial regional anatomy is also required. All procedural team members should maintain an understanding of the procedures and technologies involved. Although the minimum training for these procedures may initially be prescribed by FDA approval requirements, competence in atrial septal puncture and proper handling of devices inside the left atrium to prevent air embolization and clot formation should be considered prerequisites. A detailed review of all the skillsets necessary for these procedures as well as the means of acquiring them is beyond the scope of this document.
The team should be structured to permit the consideration of all of the available therapeutic options to the patient individualized to the risks and benefits of these approaches based upon available data. A tailored approach, with input from all relevant clinicians, may be facilitated by multidisciplinary conferences designed for case discussion and the development of consensus treatment recommendations.
Facilities
The institution should have an established structural heart disease and/or EP program with an 3) A CT laboratory with CT technologists and specialists skilled in obtaining high-quality cardiac studies of the heart for procedures where CT imaging is considered as part of the evaluation (e.g. LARIAT). Preferably CT studies would be gated to optimize image resolution.
4)
A cardiac surgeon and anesthesiologist on site available for surgical backup.
5) Cardiac surgery operating rooms in reasonable proximity to the room in which the procedure is being performed and readily accessible.
6) A room of sufficient size to accommodate all the necessary equipment and personnel.
7) The full array of equipment necessary to conduct structural heart disease interventions and device retrieval within the procedural suite.
8) An intensive care facility with staff trained to provide post-procedural observation and management.
Operator Training
Device manufacturers often provide training for the use of advanced technologies. However, it is incumbent on professional societies to set minimal performance standards for LAA procedures, specific guidance for LAA occlusion devices. Thus, specific recommendations for training in LAA occlusion need to be developed. Unanswered questions concern the requisite prior training and experience (e.g., in trans-septal puncture), the type and duration of training for LAA occlusion, the number of cases needed for initial training, maintenance of competence, funding, team-based training needs, and the expectations for procedural specialists who might be interested in performing these procedures as well as for surgeons. The establishment of such training criteria, procedural volumes, and performance and evaluation metrics is beyond the scope of this document.
Protocols for Care
Specific protocols for pre-, intra-, and post-procedural patient assessment and care should be in The FDA approval for the WATCHMAN device included requirements for 3 postapproval studies, including 1) a continued follow-up of the cohorts in the PREVAIL, CAP, and CAP2 investigational device exemption studies; 2) a new enrollment study of 1,000 patients with 2-year clinical follow-up and 5-year claims follow-up through linkage with CMS claims data; and 3) a novel surveillance study of an additional 1,000 patients enrolled in a registry with 12 months of clinical follow-up and 5 years of claims follow-up through linkage with CMS claims data (27) .
The latter 2 registry-based studies are patterned after the TVT registry, reflecting the success of the registry in providing meaningful insights into procedural safety and outcomes. By definition, these studies are limited to the WATCHMAN device. A registry would optimally be "device agnostic," designed to capture data for all patients undergoing percutaneous left atrial closure regardless of the technology employed.
In the case of the TVT Registry, the CMS NCD has stimulated registry participation. In the absence of an NCD for LAA occlusion devices, other mechanisms would be necessary to produce the data required for evaluating the safety and effectiveness of these technologies in the "real world." A national registry would also provide the platform for post-market surveillance studies requested by the FDA during approval processes and would provide payers with a mechanism to collect robust, consistent data in this patient population. It is acknowledged that registry participation requires resources for both potential subscription fees and data abstraction 
